Last checked at 1 Jun 2020 07:00
1 June 2020
Microsaic Systems plc
("Microsaic" or the "Company")
Posting of Annual Report & Notice of Annual General Meeting
Microsaic Systems plc (AIM:MSYS), the developer of point of need mass spectrometry ("MS") instruments, announces that its 2019 Annual Report, including the notice of the 2020 Annual General Meeting ("Notice of AGM"), is available for viewing on the Company's website at https://www.microsaic.com/investors/documents/. These items will be posted to shareholders today, together with the Form of Proxy for voting at the AGM.
The Company will hold its AGM at GMS House, Boundary Road, Woking, Surrey, GU21 5BX on 25 June 2020 at 11.00 am.
Under normal circumstances, the Board values greatly the opportunity to meet shareholders in person. However, the Board considers the safety and wellbeing of both its shareholders and employees to be of paramount importance and with this in mind, has made arrangements to comply with the current measures regarding restrictions on travel, limited gatherings and the 'stay at home' instructions introduced by the UK Government.
The Chairman of the meeting and one other person will attend the AGM thus fulfilling the requirement of the Company's Articles of Association for a quorum to be present consisting of two persons entitled to vote upon the business to be transacted, present in person or by proxy. Accordingly, other shareholders and proxies for shareholders will not be permitted to attend the AGM and shareholders are instead urged to submit the Form of Proxy instead. Details on submitting the Form of Proxy are contained in the Notice of AGM and its accompanying Notes.
The Board always welcomes questions from shareholders at the AGM. This year, shareholders should submit their questions directly to the Company in advance of the meeting. Shareholders should submit questions up until 11.00 am on 23 June 2020 by emailing them to info@microsaic.com. The Company will publish relevant questions received, together with answers, on the Company's website as soon as practicable after the deadline for receipt. The questions may be grouped into generic classes as the Directors deem appropriate and answers will not include any inside information as defined by the Market Abuse Regulation.
Details of the resolutions to be proposed at the AGM are set out in the Notice of AGM, which also includes explanatory notes for each resolution. The resolutions are normal routine items, except for resolution 5. Resolution 5 seeks the annual renewal of the authority for the Directors to allot securities for cash, and follows the recently revised guidelines of the Pre-Emption Group regarding the proportion of share capital which may be issued to raise funds for general corporate purposes without first offering such new shares first to existing shareholders.
The results of voting on the resolutions at the AGM will be announced shortly after the meeting and will subsequently be made available on the Company's website.
The Board will continue to monitor COVID-19 developments as well as any further UK Government advice and will issue a further statement if the above arrangements require any amendment.
Enquiries:
Microsaic Systems plc | +44 (0) 1483 751 577 |
Glenn Tracey, CEO |
|
Bevan Metcalf, FD
|
|
N+1 Singer (Nominated Adviser & Joint Broker) | +44 (0)20 7496 3000 |
Aubrey Powell / George Tzimas (Corporate Finance) |
|
Tom Salvesen (Corporate Broking)
|
|
WH Ireland Limited (Joint Broker) | +44 (0)20 7220 1666 |
James Joyce (Corporate Finance) |
|
Jasper Berry (Corporate Broking)
|
|
About Microsaic Systems
Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing, and have applications in environmental testing, chemical reaction monitoring, and academic teaching. The Company is working with a range of established global life science OEM partners, distributors and research organisations to co-develop and commercialise new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.
Microsaic's core products, the 4500 MiD®, and MiD®ProteinID are robust and compact MS systems, retaining the functionality of larger conventional MS systems, easier to use by non-specialists, consuming less energy and having lower running costs. For more information, please go to www.microsaic.com.